Clinical trials located in

Mönchengladbach

Mönchengladbach city is located in Germany. Currently, 14 clinical trials are being conducted in this city.

Mönchengladbach, located in North Rhine-Westphalia, Germany, is a city rich in history and culture. Founded in the 10th century, it boasts a blend of historical and modern architecture. The city is renowned for its textile industry heritage, symbolized by the Textile Museum. Mönchengladbach is also home to Borussia Mönchengladbach, a top-tier football club with a passionate fan base. The Abteiberg Museum, a masterpiece of contemporary architecture, houses a significant collection of modern art. Additionally, the city’s numerous parks and green spaces, like the Bunten Garten, offer serene escapes within the urban landscape.

  • CT-EU-00057210

    Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Study on customized therapy for advanced solid tumors

    The research study, now in its second phase, aims to examine if particular treatments, or treatment combinations, are safe and useful in treating certain hard-to-remove or spreading tumors. These treatments are personalized, chosen depending on certain genetic changes detected in a person’s tumor. It will take about 4 weeks to see if the treatment is successful. As part of the study, patients will have to answer some questions about their physical, emotional, mental, and social health, which will help paint a clear picture of their overall quality of life. Lastly, any negative impacts causes by the treatment are taken note of and classified according to their severity.

    • Divarasib/GDC-6036
    • Ipatasertib
    • Idasanutlin
    • Belvarafenib
    • Camonsertib
    • Pralsetinib
    • Entrectinib
    • Alectinib
    • Atezolizumab
    • Inavolisib
    • Trastuzumab Emtansine
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study new combination therapy in advanced lung cancer

    This study is about testing a new drug mix to help people with advanced lung cancer (NSCLC) that doesn’t have special gene changes. The research aims to determine whether a combination of three drugs, namely Datopotamab Deruxtecan (Dato-DXd), Durvalumab, and Carboplatin, demonstrates superior efficacy compared to an alternative drug mixture. The people in this study have stage IIIB, IIIC, or IV lung cancer. They will be split in two groups. One group will get Datopotamab Deruxtecan, Durvalumab, and Carboplatin. The other group gets Pembrolizumab and some specific chemo drugs. he primary objective is to assess whether the new three-drug combination can effectively delay cancer growth and extend overall survival time.

    • Datopotamab deruxtecan (Dato-DXd)
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Durvalumab
    • Paclitaxel
  • Exploring chronic lymphocytic leukemia treatments: acalabrutinib, obinutuzumab, venetoclax in new trial

    This clinical trial compares two drug combinations for treating high-risk chronic lymphocytic leukemia (CLL). It’s a Phase 3 study, focusing on patients who haven’t received prior treatment. Participants will either receive a triple combination of acalabrutinib, obinutuzumab, and venetoclax (GAVe) or a double combination of obinutuzumab and venetoclax (GVe). The main goal is to see if the triple combination can better prolong the time patients live without their disease getting worse, compared to the double combination.

    • Obinutuzumab
    • Acalabrutinib
    • Venetoclax
  • Discovering new treatments for breast cancer with trastuzumab deruxtecan

    This clinical trial is evaluating a new treatment, Trastuzumab Deruxtecan (T-DXd), for early-stage, HER2-positive breast cancer. The study compares T-DXd alone or in sequence with other treatments against the standard therapy. It’s designed for patients with high-risk, non-metastatic breast cancer and aims to find out if T-DXd is more effective and safe. The focus is on how well patients respond to the treatment and their overall and disease-free survival rates.

    • Doxorubicin
    • Trastuzumab deruxtecan
    • Cyclophosphamide
    • Trastuzumab
    • Pertuzumab
    • Paclitaxel
  • Testing Durvalumab alongside radiotherapy for lung cancer patients

    This study focuses on elderly or frail Stage III lung cancer patients who cannot undergo chemotherapy. It tests the combination of Durvalumab, an immunotherapy drug, with two types of radiotherapy: standard and a shorter, concentrated method. The aim is to evaluate the treatment’s safety, effectiveness, and its impact on the immune system. Monitoring includes checking for pneumonitis, tumor size, disease spread, and patient quality of life every 3 months. The study seeks to determine if this combination can control cancer growth and improve patient well-being.

    • Durvalumab
  • Study of drug combinations for advanced lung cancer

    This study is about a new combination of medical treatments, Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab and Carboplatin, intended to help people with severe lung cancer (NSCLC). This type of lung cancer lacks specific alterations in its genes that can be targeted by other forms of treatment. The scientists are testing whether this new combination of medicines can be better than another common treatment combination, Pembrolizumab and platinum-based chemotherapy. The researchers will measure the time people can live without their disease getting worse (Progression Free Survival or PFS) and the total time they survive (Overall Survival or OS) to check which treatment is superior. These periods will be monitored with special criterias set up by the medical community. The study will also observe how long people respond to the treatment (Duration of Response or DoR) and how many have an observable reaction to the treatment (Objective Response Rate or ORR). Additionally, they will be analyzing the concentration of Dato-DXd and other components in the blood to inspect the body’s interaction with this treatment.

    • Datopotamab deruxtecan
    • Pemetrexed
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Durvalumab
    • Paclitaxel
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    • Dato-DXd
    • Pembrolizumab
    • Capecitabine
    • Durvalumab
  • Testing a new trio of drugs for advanced and metastatic breast cancer

    This study, known as CAPItello-292, is testing a new combination of drugs to see if it can help treat advanced or spreading breast cancer. The drugs include one called capivasertib along with two others known as CDK4/6 inhibitors and another drug called fulvestrant. The study wants to see how well these work together and how safe they are. Firstly, they need to decide on the best dose of these drugs to use together. Then, the main part of the study will compare these drugs with the usual treatment – either of the CDK4/6 inhibitors with fulvestrant — to see which is better. Scientists will check the blood of the patients to see how much of the drugs are present. They also want to see how many people have side effects and how severe these are. Patients’ health will also be monitored, including heart tests, blood tests and checking vital signs. The ultimate goal is to see if this new treatment can slow down the growth of the cancer, or even shrink it. In simpler words, this is a study for people with a type of advanced breast cancer. It’s testing three drugs together — capivasertib, a CDK4/6 inhibitor, and fulvestrant. This study is made up of two parts. The first part is to decide on the right amount of these drugs to give at the same time. Then, they’ll test this against the usual treatment to see if it’s better. They’ll use blood tests to check how much of the drugs are in the body and will carefully watch for any side effects. They’ll also keep a close eye on people’s health overall. The main aim is to see if this new combination can stop the cancer from getting worse. The CAPItello-292 trial is aimed at patients with serious breast cancer that has started to spread. In this research, a new blend of three medicines, capivasertib, a CDK4/6 inhibitor, and fulvestrant, is being evaluated. First, researchers want to figure out the optimal dosing of these drugs when taken together. Then they’ll compare this combination to the standard treatment to see if it provides any additional benefits. They’ll take blood tests to track the amount of medication and continuously monitor for any potential side effects. The end goal is to see if this new drug mixture can slow or even decrease the growth of the cancer.

    • Capivasertib
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Fulvestrant
  • Myeloma study: lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab

    A groundbreaking study for newly diagnosed multiple myeloma patients is assessing whether a subcutaneous form of the drug isatuximab is as effective as the intravenous version. This study combines isatuximab with three other medications, lenalidomide, dexamethasone and bortezomib, in an approach known as induction therapy. The goal is to enhance patient comfort and maintain treatment effectiveness, potentially leading to an excellent partial response or better in patients eligible for stem cell transplants.

    • Dexamethasone
    • Isatuximab
    • Lenalidomide
    • Bortezomib
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Germany:

.